Investor Alley Inc.

Penny Stocks in the News: (PINKSHEETS: NSRGY), (OTCQB: AMBS)

 

New York, NY -- (ReleaseWire) -- 01/16/2013 -- Nestle SA Reg Shs. Ser. B Spons (ADR) (PINKSHEETS: NSRGY) is rolling out Purina Pro Plan Sport in the United States to help hone the fitness levels of healthy dogs that already enjoy an energetic lifestyle with their owners.

The range, which has been developed by animal scientists and nutritionists, comprises three different formulas: ‘active’ for dogs that exercise every day, ‘advanced’ for more athletic dogs, and ‘performance’ for those taking part in competitions.

Nestle SA is a Swiss Company engaged in the nutrition, health and wellness sectors. Nestlé completed its acquisition of Pfizer Nutrition, enhancing its position in global infant nutrition.

Get everything traders and investors need on NSRGY by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=NSRGY

Amarantus Biosciences Inc. (OTCQB: AMBS) closed at $ 0.100 down by $0.010 or 9.50% on a volume of 12.95M shares versus an average volume of 22.78M.

Amarantus BioScience, Inc. (AMBS) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.

The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders.

Earlier this week Amarantus BioScience presented positive preclinical efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease.

Find out more on AMBS by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=AMBS

About WallStreetReport.net
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetReport.net

Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.

BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

Contact Info:
Michael Baine
WALL STREET REPORT
info@WallStreetReport.net
347-905-5009